Open Payments

Yale-new Haven Hospital

Type
Teaching hospital
Where
New Haven, CT
Medicare CCN
070022
Received
$2,426,488 in 170 records, 2024 ($328,526 general, $2,097,962 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment92$328,526
2024Research payment78$2,097,962

By company

CompanyRecordsAmountYears
ABBVIE INC.3$259,4862024
PFIZER INC.37$236,1472024
United Imaging Healthcare North America, Inc.1$227,2272024
Servier BioInnovation1$198,9252024
Bracco Diagnostics Inc.1$170,9372024
Beckman Coulter, Inc.2$165,0612024
Siemens Medical Solutions USA, Inc.8$157,3082024
ARGENX US, INC.2$148,5962024
Takeda Pharmaceuticals U.S.A., Inc.11$127,7452024
E.R. Squibb & Sons, L.L.C.8$95,7402024
BeiGene, Ltd.4$72,8562024
National Marrow Donor Program5$65,5752024
Sage Therapeutics, LLC1$59,6002024
Caption Health, Inc.1$53,5042024
Draeger Medical Systems, Inc5$39,4682024
Novartis Pharmaceuticals Corporation6$39,3332024
Karyopharm Therapeutics Inc.8$39,0092024
TransMedics, Inc.6$34,3412024
Gen-Probe, Inc.1$28,2052024
AstraZeneca Pharmaceuticals LP1$25,0002024
KLS-Martin L.P.4$23,3692024
Boston Scientific Corporation1$20,3422024
Intuitive Surgical, Inc.2$20,0002024
Diagnostica Stago, Inc1$16,8592024
Genentech USA, Inc.1$15,0002024
ClearPoint Neuro, Inc.1$12,1912024
ARRAY BIOPHARMA INC1$10,0002024
SERVIER PHARMACEUTICALS LLC1$10,0002024
Abbott Laboratories8$6,7002024
Biogen, Inc.1$5,8192024
Stryker Corporation3$5,5842024
Eisai Inc.2$5,1252024
Medical Device Business Services, Inc.2$5,0202024
McKesson Drug Company LLC1$5,0002024
Incyte Corporation1$5,0002024
Eli Lilly and Company1$4,6382024
Olympus America Inc.11$3,7652024
Barco, Inc.2$2,9962024
M.A. Med Alliance S.A.1$1,8002024
Organon Llc1$1,4002024
Amgen Inc.1$8422024
Alexion Pharmaceuticals, Inc.6$4922024
Regeneron Pharmaceuticals, Inc.3$2252024
SANOFI US SERVICES INC.1$2002024
Becton, Dickinson and Company1$502024

By nature of payment

NatureRecordsAmount
Research payment78$2,097,962
Compensation for services other than consulting, including serving as faculty or as a speaker at a v18$155,567
Space rental or facility fees (teaching hospital only)9$53,000
Long term medical supply or device loan8$42,514
Grant7$31,620
Debt forgiveness15$27,134
Education28$11,700
Charitable Contribution6$5,475
Royalty or License1$1,514

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Siemens Medical Solutions USA, Inc.$49,706Research paymentIn-kind items and servicesBiograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR)Enhancing Corrections for Cardiac PETCT in Infiltrative Cardiomyopathy2024
2024-12-31Siemens Medical Solutions USA, Inc.$37,856Research paymentIn-kind items and servicesBiograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR)Personalized Task based Respiratory Motion Correction for Low Dose2024
2024-12-31Siemens Medical Solutions USA, Inc.$32,159Research paymentIn-kind items and servicesBiograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR)PETCT Imaging of Peripheral Arterial Disease2024
2024-12-31Diagnostica Stago, Inc$16,859Research paymentIn-kind items and servicesST GENESIA Device, global hemostasisCatheter-Related Early Thromboprophylaxis with Enoxaparin (CRETE) Studies2024
2024-12-31Siemens Medical Solutions USA, Inc.$14,383Research paymentIn-kind items and servicesBiograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR)Right Ventricular RV Hemodynamics in Patients with Sleep Apnea to Guide Therapy2024
2024-12-31Stryker Corporation$2,394Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$2,394Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$796Long term medical supply or device loanIn-kind items and servicesNA Device, PATIENT HANDLING - PH2024
2024-12-20SANOFI US SERVICES INC.$200Charitable ContributionCash or cash equivalent2024
2024-12-19BeiGene, Ltd.$10,408Research paymentIn-kind items and servicesTEVIMBRA Drug, OncologyPhase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-B12024
2024-12-18Abbott Laboratories$250Research paymentCash or cash equivalentDiamondback Coronary Device, VASCULARECLIPSE2024
2024-12-16Olympus America Inc.$0Debt forgivenessIn-kind items and servicesEVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology2024
2024-12-10ABBVIE INC.$129,743Research paymentIn-kind items and servicesELAHERE Drug, ONCOLOGYMIRV/carboplatin neo-adjuvant therapy in newly diagnosed ovarian cancer2024
2024-12-05Bracco Diagnostics Inc.$170,937Research paymentCash or cash equivalentProHance Drug, Diagnostic ImagingAN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED2024
2024-11-21PFIZER INC.$37,012Research paymentCash or cash equivalentNHCRU YNH INVOICES MAYSEP2024
2024-11-21Siemens Medical Solutions USA, Inc.$3,000GrantCash or cash equivalent2024
2024-11-18Draeger Medical Systems, Inc$32,189Research paymentCash or cash equivalentSTIMIT Activator 1 Pivotal Study2024
2024-11-18Draeger Medical Systems, Inc$3,923Research paymentCash or cash equivalentSTIMIT Activator 1 Pivotal Study2024
2024-11-14TransMedics, Inc.$1,200Research paymentCash or cash equivalentOrgan Care System Device, DeviceOCSHEART-01-ClinPAS2024
2024-11-08BeiGene, Ltd.$20,816Research paymentIn-kind items and servicesTEVIMBRA Drug, OncologyPhase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-B12024
2024-11-08TransMedics, Inc.$20,388Research paymentCash or cash equivalentOrgan Care System Device, DeviceOCSHEART-OHP-II2024
2024-11-08TransMedics, Inc.$1,800Research paymentCash or cash equivalentOrgan Care System Device, DeviceOCSHEART-OHP-II2024
2024-11-06Takeda Pharmaceuticals U.S.A., Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-10-29Servier BioInnovation$198,925Research paymentIn-kind items and servicesTibsovo Drug, OncologyPHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATI2024
2024-10-29Abbott Laboratories$650Research paymentCash or cash equivalentDiamondback Coronary Device, VASCULARECLIPSE2024
2024-10-25National Marrow Donor Program$15,095Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-10-15KLS-Martin L.P.$11,402Debt forgivenessCash or cash equivalentIPS, IMPLANT, CRANIAL, 00087, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis2024
2024-10-15KLS-Martin L.P.$1,975Debt forgivenessCash or cash equivalentIPS, SUPPLEMENTAL MODEL, FULL, 00007, QTY: 001 EA Device, Osteosynthesis2024
2024-10-09PFIZER INC.$125EducationIn-kind items and services2024
2024-10-02SERVIER PHARMACEUTICALS LLC$10,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-10-02Becton, Dickinson and Company$50Charitable ContributionCash or cash equivalent2024
2024-09-27Olympus America Inc.$0Debt forgivenessIn-kind items and servicesEVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology2024
2024-09-26Sage Therapeutics, LLC$59,600Research paymentCash or cash equivalentZULRESSO Drug, PSYCHIATRY/PSYCHOLOGYUtility of Brexanolone to target stress-induced alcohol use among men and women with Posttraumatic Stress Disorder2024
2024-09-25Organon Llc$1,400Long term medical supply or device loanIn-kind items and servicesJADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING2024
2024-09-25Barco, Inc.$1,005Long term medical supply or device loanIn-kind items and services2024
2024-09-19BeiGene, Ltd.$31,224Research paymentIn-kind items and servicesTEVIMBRA Drug, OncologyPhase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-B12024
2024-09-13Siemens Medical Solutions USA, Inc.$1,514Royalty or LicenseCash or cash equivalent2024
2024-09-10BeiGene, Ltd.$10,408Research paymentIn-kind items and servicesTEVIMBRA Drug, OncologyPhase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-B12024
2024-09-04Takeda Pharmaceuticals U.S.A., Inc.$8,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-09-01PFIZER INC.$125EducationIn-kind items and services2024
2024-08-31Regeneron Pharmaceuticals, Inc.$100Charitable ContributionCash or cash equivalent2024
2024-08-29PFIZER INC.$125EducationIn-kind items and services2024
2024-08-28ABBVIE INC.$64,871Research paymentIn-kind items and servicesELAHERE Drug, ONCOLOGYMIRV/carboplatin neo-adjuvant therapy in newly diagnosed ovarian cancer2024
2024-08-27Beckman Coulter, Inc.$136,175Research paymentCash or cash equivalentTriage Clinical Decision Support Impact Study2024
2024-08-27E.R. Squibb & Sons, L.L.C.$13,928Research paymentCash or cash equivalentA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibr2024
2024-08-23Eisai Inc.$125EducationCash or cash equivalent2024
2024-08-22PFIZER INC.$125EducationIn-kind items and services2024
2024-08-21PFIZER INC.$125EducationIn-kind items and services2024
2024-08-15PFIZER INC.$43,900Research paymentCash or cash equivalentNHCRU YNH INVOICES2024
2024-08-15PFIZER INC.$5,336Research paymentCash or cash equivalentA PHASE 1 OPENLABEL RANDOMIZED 5PERIOD 6SEQUENCE CROSSOVER STUDY TO COMPARE THE SINGLEDOSE PHARMACOKINETICS OF IMMEDIATE2024
2024-08-15Medical Device Business Services, Inc.$1,004GrantCash or cash equivalent2024
2024-08-06ABBVIE INC.$64,871Research paymentIn-kind items and servicesELAHERE Drug, ONCOLOGYMIRV/carboplatin neo-adjuvant therapy in newly diagnosed ovarian cancer2024
2024-07-30United Imaging Healthcare North America, Inc.$227,227Research paymentCash or cash equivalent2024
2024-07-26National Marrow Donor Program$18,050Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-07-24ARGENX US, INC.$99,064Research paymentCash or cash equivalentAChR autoantibody-mediated complement activity in MG patients2024
2024-07-24Alexion Pharmaceuticals, Inc.$70Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-07-15Draeger Medical Systems, Inc$1,500Research paymentCash or cash equivalentSTIMIT Activator 1 Pivotal Study2024
2024-07-12Siemens Medical Solutions USA, Inc.$6,230Research paymentCash or cash equivalentAtellica IM AMH Analytical and Clinical Study2024
2024-07-10ARGENX US, INC.$49,532Research paymentCash or cash equivalentAChR autoantibody-mediated complement activity in MG patients2024
2024-07-10PFIZER INC.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-07-10PFIZER INC.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-07-10PFIZER INC.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-07-10PFIZER INC.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-07-05TransMedics, Inc.$9,854Research paymentCash or cash equivalentOrgan Care System Device, DeviceOCSHEART-01-ClinPAS2024
2024-07-05TransMedics, Inc.$849Research paymentCash or cash equivalentOrgan Care System Device, DeviceOCSHEART-01-ClinPAS2024
2024-07-04Karyopharm Therapeutics Inc.$19,500Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2024
2024-07-04Karyopharm Therapeutics Inc.$5,000Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2024
2024-07-04Karyopharm Therapeutics Inc.$5,000Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2024
2024-07-04Karyopharm Therapeutics Inc.$3,000Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2024
2024-07-04Karyopharm Therapeutics Inc.$2,500Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2024
2024-07-04Karyopharm Therapeutics Inc.$1,800Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2024
2024-07-04Karyopharm Therapeutics Inc.$1,215Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2024
2024-07-04Karyopharm Therapeutics Inc.$994Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2024
2024-06-27ARRAY BIOPHARMA INC$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-06-25Biogen, Inc.$5,819Research paymentCash or cash equivalentA Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON)2024
2024-06-25PFIZER INC.$125EducationIn-kind items and services2024
2024-06-24Abbott Laboratories$1,500Research paymentCash or cash equivalentDiamondback Coronary Device, VASCULARECLIPSE2024
2024-06-24Abbott Laboratories$500Research paymentCash or cash equivalentDiamondback Coronary Device, VASCULARECLIPSE2024
2024-06-24Abbott Laboratories$500Research paymentCash or cash equivalentDiamondback Coronary Device, VASCULARECLIPSE2024
2024-06-14PFIZER INC.$125EducationIn-kind items and services2024
2024-06-14PFIZER INC.$125EducationIn-kind items and services2024
2024-06-10E.R. Squibb & Sons, L.L.C.$3,600GrantCash or cash equivalent2024
2024-06-10Takeda Pharmaceuticals U.S.A., Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-06-04PFIZER INC.$75EducationIn-kind items and services2024
2024-06-03PFIZER INC.$75EducationIn-kind items and services2024
2024-05-31Regeneron Pharmaceuticals, Inc.$25Charitable ContributionCash or cash equivalent2024
2024-05-29Alexion Pharmaceuticals, Inc.$70Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-05-28Draeger Medical Systems, Inc$1,355Research paymentCash or cash equivalentSTIMIT Activator 1 Pivotal Study2024
2024-05-20PFIZER INC.$125EducationIn-kind items and services2024
2024-05-17PFIZER INC.$125EducationIn-kind items and services2024
2024-05-17PFIZER INC.$125EducationIn-kind items and services2024
2024-05-16PFIZER INC.$27,215Research paymentCash or cash equivalentA PHASE 1 RANDOMIZED OPENLABEL 3PERIOD CROSSOVER SINGLEDOSE 2PART STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFEC2024
2024-05-15Takeda Pharmaceuticals U.S.A., Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-05-15Alexion Pharmaceuticals, Inc.$140Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-05-14PFIZER INC.$125EducationIn-kind items and services2024
2024-05-14PFIZER INC.$125EducationIn-kind items and services2024
2024-05-14PFIZER INC.$125EducationIn-kind items and services2024
2024-05-10Siemens Medical Solutions USA, Inc.$12,460Research paymentCash or cash equivalentAtellica IM 1300 Analyzer Device, DX - Diagnostics incl. all products and servicesAtellica IM AMH Analytical and Clinical Study2024
2024-05-10McKesson Drug Company LLC$5,000Charitable ContributionCash or cash equivalent2024
2024-05-06PFIZER INC.$50EducationIn-kind items and services2024
2024-05-02E.R. Squibb & Sons, L.L.C.$15,035Research paymentCash or cash equivalentA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibro2024
2024-04-30Regeneron Pharmaceuticals, Inc.$100Charitable ContributionCash or cash equivalent2024
2024-04-29KLS-Martin L.P.$7,796Debt forgivenessCash or cash equivalentIPS, IMPLANT, CRANIAL, 00089, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis2024
2024-04-29PFIZER INC.$5,113Research paymentCash or cash equivalentA PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED CROSSOVER FIRSTINHUMAN STUDY TO ASSESS THE SAFETY TOLERAB2024
2024-04-29KLS-Martin L.P.$2,195Debt forgivenessCash or cash equivalentIPS, SUPPLEMENTAL MODEL, FULL, 00007, QTY: 001 EA Device, Osteosynthesis2024
2024-04-28PFIZER INC.$100EducationIn-kind items and services2024
2024-04-26National Marrow Donor Program$9,950Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-04-24Alexion Pharmaceuticals, Inc.$72Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-04-19National Marrow Donor Program$5,500Research paymentCash or cash equivalentA Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for N2024
2024-04-19PFIZER INC.$4,000EducationIn-kind items and services2024
2024-04-18E.R. Squibb & Sons, L.L.C.$10,000GrantCash or cash equivalentOPDIVO Biological, Oncology2024
2024-04-18E.R. Squibb & Sons, L.L.C.$5,000GrantCash or cash equivalent2024
2024-04-10PFIZER INC.$45,591Research paymentCash or cash equivalent2024
2024-04-10M.A. Med Alliance S.A.$1,800Research paymentCash or cash equivalentSELUTION SLR DEB 014 Device, CARDIOVASCULARA Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR 0142024
2024-04-09Incyte Corporation$5,000EducationCash or cash equivalent2024
2024-04-02E.R. Squibb & Sons, L.L.C.$33,714Research paymentCash or cash equivalentSOTYKTU Drug, ImmunologyA Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With SLE2024
2024-04-01PFIZER INC.$100EducationIn-kind items and services2024
2024-04-01PFIZER INC.$75EducationIn-kind items and services2024
2024-03-29TransMedics, Inc.$250Research paymentCash or cash equivalentOrgan Care System Device, DeviceOCS-CAR-032020192024
2024-03-27Alexion Pharmaceuticals, Inc.$35Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-03-25Gen-Probe, Inc.$28,205Research paymentCash or cash equivalentPANTHER FUSION Device, DiagnosticsMethod Comparison Study Protocol for the Panther Fusion GI Panels2024
2024-03-21E.R. Squibb & Sons, L.L.C.$13,097Research paymentCash or cash equivalentPhase I/II FIH Monotherapy/Combination2024
2024-03-20Boston Scientific Corporation$20,342Long term medical supply or device loanIn-kind items and servicesAVVIGO Guidance System Device, AVVIGO Guidance System2024
2024-03-20Amgen Inc.$842Research paymentIn-kind items and servicesIMDELLTRA (AMG757) Biological, HematologyP3 LS-SCLC Mono 757 vs Placebo2024
2024-03-13Intuitive Surgical, Inc.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDA VINCI SP Device, SURGERY2024
2024-03-13Alexion Pharmaceuticals, Inc.$105Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-03-12Caption Health, Inc.$53,504Research paymentCash or cash equivalent Device, Lung GuidanceLung Guidance2024
2024-03-06PFIZER INC.$50EducationIn-kind items and services2024
2024-03-05Genentech USA, Inc.$15,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentPhesgo Biological, BioOncology2024
2024-03-01E.R. Squibb & Sons, L.L.C.$1,365Research paymentCash or cash equivalentSOTYKTU Drug, ImmunologyA Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With SLE2024
2024-02-29Novartis Pharmaceuticals Corporation$21,018Research paymentCash or cash equivalentKISQALI Drug, OncologyRibociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence2024
2024-02-27Abbott Laboratories$500Research paymentCash or cash equivalentDiamondback Coronary Device, VASCULARECLIPSE2024
2024-02-26Novartis Pharmaceuticals Corporation$4,680Research paymentIn-kind items and servicesA Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an2024
2024-02-22Barco, Inc.$1,991Long term medical supply or device loan (2 payments)In-kind items and services2024
2024-02-21Eisai Inc.$5,000GrantCash or cash equivalentLenvima Drug, Oncology2024
2024-02-21Takeda Pharmaceuticals U.S.A., Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentICLUSIG Drug, ONCOLOGY2024
2024-02-21Abbott Laboratories$1,500Research paymentCash or cash equivalentDiamondback Coronary Device, VASCULARECLIPSE2024
2024-02-20PFIZER INC.$25,402Research paymentCash or cash equivalentA MULTIPART PHASE 1 STUDY WITH RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED SINGLE AND MULTIPLEDOSE ESCALATION T2024
2024-02-20Abbott Laboratories$1,300Research paymentCash or cash equivalentDiamondback Coronary Device, VASCULARECLIPSE2024
2024-02-15Medical Device Business Services, Inc.$4,016GrantCash or cash equivalent2024
2024-02-15Olympus America Inc.$280Debt forgivenessIn-kind items and servicesRHINO-LARYNGO VIDEOSCOPE Device, Ear, Nose, Throat2024
2024-02-12PFIZER INC.$75EducationIn-kind items and services2024
2024-02-12PFIZER INC.$75EducationIn-kind items and services2024
2024-02-08AstraZeneca Pharmaceuticals LP$25,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-02-06Olympus America Inc.$233Debt forgivenessIn-kind items and servicesEVES EUS ULTRASOUND BRONCHOFIBERVIDEOSCOPE Device, Gastroenterology2024
2024-02-05Takeda Pharmaceuticals U.S.A., Inc.$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-01-29Eli Lilly and Company$4,638Research paymentIn-kind items and servicesEMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATI2024
2024-01-23PFIZER INC.$75EducationIn-kind items and services2024
2024-01-17Intuitive Surgical, Inc.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDA VINCI SP Device, SURGERY2024
2024-01-12National Marrow Donor Program$16,980Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-01-12Draeger Medical Systems, Inc$500Research paymentCash or cash equivalentSTIMIT Activator 1 Pivotal Study2024
2024-01-11PFIZER INC.$75EducationIn-kind items and services2024
2024-01-09Novartis Pharmaceuticals Corporation$684Research paymentIn-kind items and servicesA Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients Wit2024
2024-01-08Takeda Pharmaceuticals U.S.A., Inc.$24,936Research paymentCash or cash equivalentTAKCLNTRL0000184: External Controls for Clinical Trials2024
2024-01-08Takeda Pharmaceuticals U.S.A., Inc.$24,936Research paymentCash or cash equivalentTAKCLNTRL0000184: External Controls for Clinical Trials2024
2024-01-08Takeda Pharmaceuticals U.S.A., Inc.$24,936Research paymentCash or cash equivalentTAKCLNTRL0000184: External Controls for Clinical Trials2024
2024-01-08Takeda Pharmaceuticals U.S.A., Inc.$24,936Research paymentCash or cash equivalentTAKCLNTRL0000184: External Controls for Clinical Trials2024
2024-01-03Takeda Pharmaceuticals U.S.A., Inc.$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-01-03Olympus America Inc.$1,191Debt forgivenessIn-kind items and servicesGASTROINTESTINAL VIDEOSCOPE Device, Gastroenterology2024
2024-01-03Olympus America Inc.$1,000Debt forgivenessIn-kind items and servicesEVIS X1 VIDEO SYSTEM CENTER Device, Gastroenterology2024
2024-01-03Olympus America Inc.$544Debt forgivenessIn-kind items and servicesEVIS EXERA III COLONOVIDEOSCOPE Device, Gastroenterology2024
2024-01-03Olympus America Inc.$176Debt forgivenessIn-kind items and servicesEVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology2024
2024-01-03Olympus America Inc.$166Debt forgivenessIn-kind items and servicesEVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology2024
2024-01-03Olympus America Inc.$99Debt forgivenessIn-kind items and servicesEVIS EXERA III COLONOVIDEOSCOPE Device, Gastroenterology2024
2024-01-03Olympus America Inc.$72Debt forgivenessIn-kind items and servicesGASTROINTESTINAL VIDEOSCOPE Device, Gastroenterology2024
2024-01-02Beckman Coulter, Inc.$28,885Research paymentCash or cash equivalentTriage Clinical Decision Support Impact Study2024
2024-01-01ClearPoint Neuro, Inc.$12,191Long term medical supply or device loanIn-kind items and servicesCLEARPOINT Device, Neurology2024
2024-01-01Novartis Pharmaceuticals Corporation$11,140Research paymentCash or cash equivalentSingle-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investiga2024
2024-01-01Novartis Pharmaceuticals Corporation$1,770Research paymentIn-kind items and servicesA Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax 2024
2024-01-01Novartis Pharmaceuticals Corporation$40Research paymentIn-kind items and servicesA Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for th2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

South Central Connecticut Planning RegionNew Haven city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
New Haven, CT
County
South Central Connecticut Planning Region, CT
State
Connecticut
Population B01003134,349570,5983,624,508
Population, 2020 census P1134,023-3,605,944
Median age B0100231.940.241.1
Under 18 B0100121.3%19.6%20.2%
65 and over B0100111.8%18.6%18.5%
Households B1100154,773230,6731,434,007
Foreign born B0500218.0%13.7%15.7%
Median household income B19013$56,851$88,197$95,781
Median family income B19113$68,668$115,384$122,706
Per capita income B19301$36,242$49,766$55,915
Poverty rate B1700123.9%11.4%10.0%
Unemployment rate B230258.4%6.0%5.6%
Civilian labor force B2302569,528307,6071,959,490
Mean commute (minutes) B0801321.523.526.5
Bachelor's degree or higher B1500338.9%42.0%42.5%
Housing units B2500160,333248,2671,541,822
Owner-occupied B2500328.4%60.5%66.5%
Renters B2500371.6%39.5%33.5%
Median home value B25077$287,100$353,100$366,900
Median gross rent B25064$1,488$1,525$1,488
White, not Hispanic B0300230.0%58.5%61.9%
Black B0300227.6%13.0%9.8%
Hispanic or Latino B0300231.0%19.5%18.3%
Asian B030025.2%4.5%4.7%
American Indian and Alaska Native B030020.2%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.